2,200
Participants
Start Date
January 31, 2015
Primary Completion Date
December 31, 2017
Study Completion Date
December 31, 2017
Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel)
"* Rivaroxaban will be orally administered after a meal at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min (regardless of time)~* Antiplatelet will be selected from aspirin or thienopyridine derivatives (clopidogrel or prasugrel)~ * Aspirin will be orally administered once a day at a dose of 81 mg or 100 mg~ * Clopidogrel will be orally administered once a day after a meal at a dose of 75 mg. The dose will be reduced to 50mg once a day depending on age, body weight or clinical findings.~ * Prasugrel will be orally administered once a day at a dose of 3.75 mg. If the body weight is 50kg or less a reduced dose(2.5 mg once a day) will be considered depending on the age, renal function or other bleeding and thrombotic risk."
Rivaroxaban
Rivaroxaban will be orally administered at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min.
RECRUITING
Japan Cardiovascular Research Foundation, Suita
Lead Sponsor
Japan Cardiovascular Research Foundation
OTHER